Weight-loss drug cuts risk of heart attack, strokes: Novo Nordisk

The trial enrolled 17,604 adults aged 45 years who were either overweight or obese, and were randomised to receive either the injected drug, or a placebo, over a period of five years.

It is the first research to suggest this class of weight loss medication, which has attracted considerable attention from the wider public, can confer lasting improvements to cardiovascular health/AFP